Welcome to our dedicated page for ITMR news (Ticker: ITMR), a resource for investors and traders seeking the latest updates and insights on ITMR stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ITMR's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ITMR's position in the market.
Itamar Medical Ltd. (NASDAQ: ITMR) announced that its WatchPAT® technology was featured in a panel discussion at Ladenburg Thalmann’s Healthcare Symposia Series, focusing on sleep apnea management. The event included expert speakers such as Dr. Omar Burschtin from Mount Sinai and Dr. Dan Bensimhon from Cone Health, who discussed the significance of sleep apnea in cardiovascular care. Itamar Medical specializes in non-invasive medical devices for sleep disorder diagnosis and offers a Total Sleep Solution to enhance patient management and reduce healthcare costs, with products available in key global markets.
Itamar Medical Ltd. (NASDAQ: ITMR) will report its Q1 2021 financial results on May 19, 2021, before U.S. market opens. The company will host a conference call at 8:00 a.m. ET to discuss these results and provide corporate updates. Itamar Medical specializes in non-invasive medical devices for diagnosing sleep disorders and offers solutions for sleep apnea management. Its key product, WatchPAT, is available in major markets including the U.S., Japan, and Europe. For more information, visit itamar-medical.com.
Itamar Medical Ltd. (NASDAQ: ITMR) reported a 31% increase in Q4 2020 revenues, totaling $12.8 million, driven by a 39% rise in U.S. WatchPAT sales to $10.2 million. The company provided 2021 revenue guidance of $52-53 million, reflecting 27-29% growth year-over-year. Despite revenue growth, the Q4 operating loss surged to $2.7 million due to rising expenses, including a 34% increase in selling and marketing costs. Non-IFRS net loss for the quarter reached $2.1 million. Itamar completed a $50 million public offering to enhance its growth capabilities and pursue strategic opportunities.
Itamar Medical Ltd. (NASDAQ: ITMR) will release its financial results for Q4 and FY 2020 on March 2, 2021, before U.S. market opening. The company provides a digital health platform for sleep apnea management integrated into cardiac care. The results will be discussed in a conference call at 8:00 a.m. ET, hosted by CEO Gilad Glick and CFO Shy Basson. Itamar is focused on non-invasive medical devices for diagnosing sleep disorders, offering its key product, WatchPAT, in major markets such as the U.S., Japan, and Europe.
Itamar Medical Ltd. (NASDAQ: ITMR) announced participation in two upcoming investor conferences. Management will present at the 10th Annual SVB Leerink Global Healthcare Conference on February 25, 2021, at 8:00 a.m. ET, and at the 41st Annual Cowen Health Care Conference on March 4, 2021, at 10:30 a.m. ET. Webcasts will be available on the company’s website. Itamar Medical focuses on non-invasive medical devices for diagnosing respiratory sleep disorders, offering a Total Sleep Solution to enhance patient care.
Itamar Medical Ltd. (Nasdaq: ITMR) announced the closing of its public offering of 3,506,499 American Depositary Shares (ADSs) at a price of $22.75 per ADS, generating approximately $50 million in gross proceeds for the company. The offering included the full exercise of the underwriters’ option for an additional 457,369 ADSs. The company sold 2,196,499 ADSs, while a shareholder sold 1,310,000 ADSs. The offering is expected to support the company’s focus on non-invasive devices for diagnosing sleep disorders.
Itamar Medical Ltd. (Nasdaq: ITMR) has priced its public offering of 3,049,130 American Depositary Shares (ADSs) at $22.75 each, aiming to raise approximately $44.8 million. The offering includes 1,968,466 ADSs from the company and 1,080,664 ADSs from shareholder Viola Growth 2 A.V. Limited Partnership. A 30-day option for underwriters to purchase an additional 457,369 ADSs has been granted. The offering is set to close on February 9, 2021. This move supports Itamar Medical's focus on enhancing its non-invasive diagnostic solutions for respiratory sleep disorders.
